Drug Trial Radar · NCT07076121
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
470
Planned (sponsor's estimate)
Start
Oct 23, 2025
Primary completion
May 3, 2029
Study completion May 3, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Conditions
- Pancreatic Ductal Adenocarcinoma
Interventions
NavlimetostatDrug
Specified dose on specified days
GemcitabineDrug
Specified dose on specified days
Nab-paclitaxelDrug
Specified dose on specified days
PlaceboDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival as assessed by Response Evaluation Criteria in Solid Tumors version v1.1 (RECIST v1.1)Time frame: Up to 3 years after last participant is randomized
- Overall Survival (OS)Time frame: Up to 3 years after last participant is randomized
Locations
269 sites in 36 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix
Phoenix, Arizona
Local Institution - 0365
Tucson, Arizona
Highlands Oncology Group
Springdale, Arkansas
Scripps Green Hospital
La Jolla, California
Local Institution - 0157
San Francisco, California
Baptist MD Anderson Cancer Center
Jacksonville, Florida
Mayo Clinic in Florida
Jacksonville, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia
St. Luke's Cancer Institute: Boise
Boise, Idaho
Local Institution - 0168
Chicago, Illinois
Local Institution - 0125
Westwood, Kansas
Local Institution - 0370
Louisville, Kentucky
Local Institution - 0371
Baltimore, Maryland
Johns Hopkins Hospital
Baltimore, Maryland
Local Institution - 0120
Boston, Massachusetts
Brigitte Harris Cancer Pavilion
Detroit, Michigan
The Cancer & Hematology Centers
Grand Rapids, Michigan
Mayo Clinic in Rochester, Minnesota
Rochester, Minnesota
University Of Nebraska Medical Center
Omaha, Nebraska
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone
Mineola, New York
NYU Winthrop Hospital
Mineola, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Local Institution - 0279
New York, New York
Wilmot Cancer Institute
Rochester, New York
University of North Carolina Medical Center
Chapel Hill, North Carolina
Local Institution - 0376
Columbus, Ohio
Kaiser Permanente Center for Health Research
Portland, Oregon
Local Institution - 0162
Portland, Oregon
St. Luke's University Health Network
Bethlehem, Pennsylvania
Local Institution - 0301
Lancaster, Pennsylvania
Thomas Jefferson University - Medical Oncology
Philadelphia, Pennsylvania
Local Institution - 0368
Pittsburgh, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
SCRI Oncology Partners
Nashville, Tennessee
Tennessee Oncology, PLLC
Smyrna, Tennessee
Texas Oncology - DFW
Dallas, Texas
Uus Oncology
Fort Worth, Texas
Showing 40 of 269 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.